TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03564340: A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 890 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$6,008,310

Rescue Site Savings

+$3,966,270

Unlock Full NCT03564340 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03564340 Rescue Dossier →